RxDoctor Payments Data

Alexander Bruscke, MD

Urogynecology and Reconstructive Pelvic Surgery · Quakertown, PANPI 1104316777

Payments from drug & device makers

What this record shows

This record is dominated by grants: $15,000 of the $23,522 with a category attached, or 63.8%. 11 manufacturers reported payments, led by Medtronic at 51.6% of the total. Reporting peaked in 2024 at $18,966 and has fallen 89.2% since, to $2,056 in 2025.

$23,522in general payments, 2019–2025

Across 148 payments — averaging $158.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$12K
  • Boston Scientific$6K
  • Coloplast$3K
  • Axonics, Inc.$1K
  • AbbVie$685
  • Astellas Pharma US Inc$416
  • plus $665 from 5 others
$551in research payments, 2019–2025

Across 1 payment — averaging $551.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$551

What the payments were for

  • Grants$15,00064%
  • Travel & lodging$1,7237%
  • Food & beverage$6,79929%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,522 in reported general payments places this provider in the 85th percentile of 51 urogynecology and reconstructive pelvic surgery providers in Pennsylvania.

See all urogynecology and reconstructive pelvic surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$2,794
Medicare patients
18
Services billed
27

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron56$39,125
MyrbetriqMirabegron58$34,155
EstringEstradiol19$9,867
Estradiol97$9,101
Mirabegron ErMirabegron12$4,918
YuvafemEstradiol16$2,562
Methenamine Hippurate14$1,140
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst76$704
Trimethoprim17$248
Fluconazole13$68
Cephalexin30$66
Ciprofloxacin Hcl14$53
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim30$46
Oxycodone Hcl21$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$148$39,12556 claims
Astellas Pharma US IncMyrbetriq$416$34,15558 claims
PfizerEstring$111$9,86719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 51 urogynecology and reconstructive pelvic surgery providers in Pennsylvania.

Other urogynecology and reconstructive pelvic surgery in Quakertown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →